Los Angeles, CA, April 11, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTC-BB:ENDV) today announced significant advancement in the of process to obtain medical reimbursements for its SofPulse® devices with its SEC filing of a $5 million Regulation A+ common stock offering currently in registration.
$5 Million Common Stock Offering for Endonovo Therapeutics Designed to Advance SofPulse® Process for Medical Reimbursement
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Apple%20Inc%20logo%20on%20Apple%20store-by%20PhillDanze%20via%20iStock.jpg)
/Elon%20Musk%2C%20founder%2C%20CEO%2C%20and%20chief%20engineer%20of%20SpaceX%2C%20CEO%20of%20Tesla%20by%20Frederic%20Legrand%20-%20COMEO%20via%20Shutterstock.jpg)